drugset / Trial / NCT06982963
Randomized, Double Blind, Placebo-controlled Phase 2 Study in Adults With Celiac Disease
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This study is a randomized, double-blind, placebo controlled clinical study to assess the efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) of FB102 in adult participants with well controlled (on a strict GFD) CeD following an oral gluten challenge.
Timeline
- Start
- 2025-08-04
- Primary completion
- 2027-02-28
- Completion
- 2027-02-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | FB102 | Unknown | 3 mg/kg | — |
| Subject | FB102 | Unknown | 5 mg/kg | — |